Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on April 1, 2025

REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting
BRAINTREE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is providing this reminder that data from the Company’s ACCESS-PVI trial will be presented by …

Clene to Present at the Jones Healthcare and Technology Innovation Conference
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the …

Cannabix Technologies to Attend U.S. National Drug and Alcohol Conference to Market Marijuana Breath Test
VANCOUVER, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report that it will …

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates …

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
SAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat …

Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025
Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic mechanism of action This investigational treatment was …

Unity Consortium Kicks Off Adolescent Immunization Action Week (AIAW25) to Help Parents and Adolescents Stay on TASK with Recommended Immunizations
AIAW 2025 Runs April 7-11 to Encourage Well-Visits and Recommended Immunizations VENTNOR CITY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- UNITY® Consortium, a non-profit dedicated to adolescent and young adult immunization and preventive health, urges …

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction Vancouver, Canada, April 01, 2025 (GLOBE NEWSWIRE) -- Clearmind …

Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations
PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings. The …

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in EuropeOperating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focusBERKELEY, Calif. and MAINZ, Germany, …

Nkarta to Participate in an April Investor Conference
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th …

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of …

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …

Phathom Pharmaceuticals Announces Leadership Succession
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven …

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company,” NASDAQ: CHRS) announced …

electroCore to Participate at the Needham Virtual Healthcare Conference
ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place …

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid …

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the …

Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2025 after the close of trading on Monday, May 5. Inspire’s management team will host a corresponding …

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics …